175 related articles for article (PubMed ID: 22193701)
1. Aliskiren displays long-lasting interactions with human renin.
Gossas T; Vrang L; Henderson I; Sedig S; Sahlberg C; Lindström E; Danielson UH
Naunyn Schmiedebergs Arch Pharmacol; 2012 Feb; 385(2):219-24. PubMed ID: 22193701
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells.
Batenburg WW; de Bruin RJ; van Gool JM; Müller DN; Bader M; Nguyen G; Danser AH
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1151-7. PubMed ID: 18388329
[TBL] [Abstract][Full Text] [Related]
4. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro.
Biswas KB; Nabi AH; Arai Y; Nakagawa T; Ebihara A; Ichihara A; Watanabe T; Inagami T; Suzuki F
Hypertens Res; 2010 Oct; 33(10):1053-9. PubMed ID: 20664543
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
[TBL] [Abstract][Full Text] [Related]
7. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
[TBL] [Abstract][Full Text] [Related]
8. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
Rebello S; Zhao S; Hariry S; Dahlke M; Alexander N; Vapurcuyan A; Hanna I; Jarugula V
Eur J Clin Pharmacol; 2012 May; 68(5):697-708. PubMed ID: 22124880
[TBL] [Abstract][Full Text] [Related]
9. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.
Stanton AV; Dicker P; O'Brien ET
Am J Hypertens; 2009 Sep; 22(9):954-7. PubMed ID: 19556972
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
Buczko W; Hermanowicz JM
Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
[TBL] [Abstract][Full Text] [Related]
12. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
13. Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin.
Lange S; Fraune C; Alenina N; Bader M; Danser AH; Frenay AR; van Goor H; Stahl R; Nguyen G; Schwedhelm E; Wenzel UO
J Hypertens; 2013 Apr; 31(4):713-9. PubMed ID: 23407438
[TBL] [Abstract][Full Text] [Related]
14. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
15. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
18. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]